Scientists find secretin has effect on some chronic liver diseases

According to a new study published in the journal Hepatology, a kind of high-level digestive hormone which is called secretin may play an important role in the management of some chronic liver diseases. This finding may lead to new ways to treat cholestatic liver disease.

Scientists team Texas A & M Health Science Center found that specific secretin receptor antagonists may reduce liver fibrosis and cholestasis animal model. Liver fibrosis (scar tissue accumulation) can eventually lead to cirrhosis, liver failure or liver cancer. But at present, there is no good treatment.

One of the research authors, Texas A & M Health Science Center Gianfranco Alpini said, "We show for the first time, and the secretin receptor antagonist can inhibit hepatic fibrosis. In addition to improving hepatic fibrosis, the antagonist can also" Close "expression of related genes, even those suffering from congenital fibrosis of the individual." Assistant Professor, Texas a & M University School of Medicine study authors Fanyin Dr. Meng said, "this work may help manage extrahepatic biliary obstruction and primary sclerosing cholangitis associated with hepatobiliary disease."

Some previous studies Alpini and his team have done show that secretin can cause bile duct (biliary epithelial cells) cell proliferation and inhibit the secretion of bile. After eating individuals without liver disease, gallbladder releases bile into the small intestine to help digestion and absorption of fat. An important part of this process is the bile duct cells, which are the only cells to produce the hormone secretin.

Alpini said the study also showed that compared to healthy individuals, cholestatic disease individuals secretin / secretin receptor pathway is activated. The next step will be more translational research, in order to explore the human individual other types of cholestatic disease. "Impact of secretin on the rest of the body (such as the brain and heart) may neuroendocrine hormone how outer onset generate new knowledge in the gastrointestinal tract.

Dr. Shannon Glaser at Texas a & M University School of Medicine said, "This is very encouraging - if we can identify bile duct cell-specific signaling pathways, then we might be able to target treatment of cholestatic disease. If detected early, maybe we can target this pathway to delay the occurrence of fibrosis, which will prevent certain liver cells to be damaged."

Go through this link: http://www.cusabio.com/Recombinant-Protein/Recombinant-Rattus-norvegicus-Rat-Transforming-growth-factor-beta-1-11106403.html